NEW YORK – Genomind and NeuroFlow today announced an agreement that combines NeuroFlow's digital health platform with Genomind's genetic testing service with the aim of improving patient wellness and reducing costs across a continuum of care for conditions that include depression, anxiety, post-traumatic stress disorder, and substance abuse, among other conditions.
Financial and other terms of the agreement were not disclosed.
The companies said that they will leverage NeuroFlow’s mental health integration platform and the Genomind Professional PGx Express mental health pharmacogenomics service to provide patients and clinicians with "actionable tools that support access to care, improve outcomes, and reduce costs in mental health treatment."
NeuroFlow’s software enables remote patient monitoring, risk stratification, and behavioral health integration across multiple medical care settings, including psychology, primary care, and pain management specialties. Genomind Professional PGx Express is a genetic test that uses a cheek swab to analyze 24 pharmacokinetic or pharmacodynamic genes.
As part of the agreement, physicians using Philadelphia-based NeuroFlow’s IntegrateHealth application will be able to administer Genomind Professional PGx Express to their patients and communicate results within the platform, including implications on treatment decisions, the firms said.
The agreement will enable physicians to use King of Prussia, Pennsylvania-based Genomind’s service to help understand patients’ genetics and how they may impact their mental health. Further, physicians will be able to use NeuroFlow’s technology applications to remotely monitor and track adherence and progress, the firms said.
Earlier this month, Genomind announced that it had expanded its mental health genetic testing services by launching Genomind Professional PGx Express to help physicians navigate the connection between a patient’s genetic biomarkers and their implications for mental health treatment. The firm said that UnitedHealthcare has issued a positive coverage decision for the use of multigene panel PGx testing, including Genomind’s service, in certain patients being treated for major depressive disorder or anxiety.